Genital Herpes (HSV-1 and HSV-2): Symptoms, Testing and Evidence-Based Treatment

Evidence reviewed: 8 November 2026. Herpes simplex virus (HSV) infection is common and often misunderstood. Both HSV-1 and HSV-2 can cause oral or genital herpes, and many people who carry the virus have no recognized symptoms. Effective antiviral medicines can shorten outbreaks and reduce recurrences, but they do not eliminate latent infection. Diagnosis, treatment and counseling should distinguish first episodes, recurrent genital disease, oral lesions, pregnancy and serious complications. This guide follows the US Centers for Disease Control and Prevention (CDC) sexually transmitted infection (STI) treatment guidance [1].

HSV-1 versus HSV-2: what is the difference?

HSV is a double-stranded DNA virus that infects epithelial cells and then establishes lifelong latency in sensory neurons. HSV-1 is frequently associated with oral herpes, while HSV-2 is more commonly associated with recurrent genital infection; however, either type can infect either site. Following a first genital episode, genital HSV-2 typically recurs and sheds virus more often than genital HSV-1. HSV can spread through direct contact with infected skin, mucosa or secretions even when an infected person has no visible sores [1,2].

Reactivation can cause tingling, burning, itching or pain followed by grouped blisters or ulcers. Physical stressors, illness and other factors may be associated with recurrences, but outbreaks cannot reliably be predicted for every individual.

Symptoms and complications

  • First recognized episode: painful genital vesicles or ulcers, burning with urination, tender groin nodes and sometimes fever or malaise. Symptoms range from mild to severe.
  • Recurrent genital herpes: localized tingling or discomfort, followed by fewer lesions and often a shorter illness than the first episode.
  • Oral herpes: painful blisters on or near the lips; primary infection can sometimes produce extensive oral inflammation.
  • Asymptomatic infection: no recognized outbreaks, yet intermittent viral shedding and transmission may still occur.

Urgent assessment is necessary for painful red eyes or light sensitivity (possible herpetic keratitis), severe headache or neck stiffness, altered consciousness, difficulty passing urine, widespread lesions, or severe infection in an immunocompromised person. Suspected neonatal HSV is a medical emergency. Never self-treat suspected eye herpes with steroid drops; prompt ophthalmological evaluation is important [1].

How is herpes diagnosed?

If a fresh blister or ulcer is present, the preferred test is a type-specific HSV nucleic acid amplification test (NAAT/PCR) from a lesion swab. It identifies HSV-1 versus HSV-2 and is more sensitive than viral culture. A negative lesion swab, especially after the lesion has begun healing, does not completely exclude infection. A blood test for type-specific HSV IgG may be useful in selected situations, but false positives—especially with low-index HSV-2 results—can occur and may require confirmatory testing. HSV IgM testing is not recommended; routine population screening without symptoms is generally not advised [1].

Clinical appearance alone is not reliably diagnostic, because other genital ulcers and skin conditions can look similar. People with genital herpes should also be offered appropriate HIV testing and assessment for other STIs when indicated [1].

How antiviral medicines work

Acyclovir and its better-absorbed prodrug valacyclovir, together with famciclovir (converted to penciclovir), inhibit herpesvirus DNA replication. Viral thymidine kinase helps activate these nucleoside analogues in infected cells; active metabolites interfere with viral DNA polymerase activity. These drugs reduce viral replication during active infection but do not eradicate HSV from neuronal latency. Oral antiviral treatment is usually more useful than topical antiviral creams for genital herpes; the CDC discourages routine topical therapy because its clinical benefit is minimal [1].

Acyclovir and valacyclovir are cleared largely through the kidneys. Dose adjustments depend on the specific drug, prescribed indication and estimated kidney function; the original article’s universal percentage reductions and advice to discontinue at arbitrary kidney-function thresholds were not supported. Clinicians should use current product-specific dosing guidance, particularly in older adults or those with renal impairment.

First clinical episode: recommended oral antiviral treatment

The CDC recommends antiviral treatment for all first clinical episodes of genital herpes, even if symptoms appear mild, because illness can become prolonged. For immunocompetent adults, guideline regimens include one of the following [1]:

Medicine CDC first-episode regimen
Acyclovir 400 mg orally three times daily for 7–10 days
Valacyclovir 1 g orally twice daily for 7–10 days
Famciclovir 250 mg orally three times daily for 7–10 days

Treatment may be extended if lesions have not fully healed after 10 days. These are guideline examples, not self-prescribing instructions; pregnancy, kidney function, immunosuppression, drug interactions and local practice can alter treatment.

Recurrent herpes: episodic versus suppressive therapy

Episodic treatment when symptoms begin

For someone with established recurrent HSV-2, a clinician may prescribe medicine to keep on hand and start during the prodrome or within one day of lesion onset. CDC options include valacyclovir 500 mg twice daily for 3 days or 1 g once daily for 5 days, as well as specified acyclovir or famciclovir regimens. These shorter courses are for recurrent episodes, not initial genital herpes [1].

Daily suppressive therapy

Daily treatment can be considered with frequent or troublesome recurrences, transmission concerns or substantial psychological burden. In people with frequent HSV-2 recurrences, suppressive therapy reduces outbreaks by approximately 70%–80%; it does not completely prevent shedding. CDC regimens for adults without HIV include [1]:

Medicine CDC suppressive regimen
Acyclovir 400 mg orally twice daily
Valacyclovir 500 mg orally once daily, or 1 g once daily
Famciclovir 250 mg orally twice daily

Valacyclovir 500 mg daily can be less effective if there are 10 or more recurrences a year. Suppressive valacyclovir has been shown to reduce HSV-2 transmission in certain couples where one partner has symptomatic genital HSV-2, but does not eliminate transmission risk. For genital HSV-1, shedding and recurrence are generally less frequent; suppressive treatment is generally reserved for frequent recurrences or important individualized circumstances [1].

Reducing transmission and protecting partners

  • Inform sexual partners and discuss HSV type, outbreak history and prevention.
  • Avoid vaginal, anal or oral sexual contact during lesions or warning symptoms such as burning or tingling.
  • Use condoms and other barriers consistently: they reduce, but do not eliminate, the risk because lesions and shedding can occur outside covered skin.
  • Discuss daily suppressive treatment when appropriate, especially in symptomatic HSV-2 infection.
  • Do not assume lack of symptoms means no possibility of transmission.

There is no currently licensed preventive vaccine for HSV. HSV-2 infection may increase susceptibility to HIV acquisition, so an STI and HIV-prevention discussion is appropriate [1].

Herpes during pregnancy and risk to the newborn

Newly acquired genital HSV near the time of delivery carries a greater neonatal transmission risk than established recurrent infection. Pregnant patients should tell their obstetric team about genital herpes history, possible new lesions and exposure. CDC guidance recommends starting suppressive treatment at 36 weeks for pregnant people with a history of recurrent genital herpes: acyclovir 400 mg orally three times daily or valacyclovir 500 mg orally twice daily [1]. This reduces recurrences at delivery but does not guarantee neonatal protection.

At labor, clinicians assess for active genital lesions or prodromal symptoms. Cesarean delivery is recommended if genital lesions or prodromal symptoms are present at labor under CDC guidance. Delivery planning depends on the clinical context; a history of herpes alone does not automatically require cesarean delivery. Newborns with suspected HSV need urgent specialist assessment and, when indicated, intravenous acyclovir [1].

Special cases: immunosuppression and antiviral resistance

People with HIV or other immunocompromising conditions may develop extensive lesions, delayed healing or treatment-resistant infection. Management may require higher or more frequent oral antiviral doses, hospitalization or intravenous therapy, depending on severity. Acyclovir resistance is particularly relevant when lesions persist despite correctly taken treatment. CDC guidance recommends obtaining a viral culture for phenotypic susceptibility testing and consulting an infectious disease specialist; acyclovir-resistant strains are generally resistant to valacyclovir and often to famciclovir. Foscarnet is a specialist treatment option, not an at-home alternative [1].

Frequently asked questions

Does HSV-1 only cause cold sores?

No. HSV-1 can also cause genital infection, including through oral-genital contact [1,2].

Can medicine cure genital herpes permanently?

No. Antivirals shorten episodes and reduce recurrences but do not remove latent HSV from sensory neurons.

Should every positive HSV blood test lead to daily medication?

No. Test reliability, symptoms, HSV type, pregnancy status and personal preferences matter. People with asymptomatic seropositivity do not automatically need suppressive antivirals [1].

Can HSV spread without visible blisters?

Yes. Asymptomatic shedding occurs. Barriers, avoiding contact during outbreaks and appropriate suppressive treatment can reduce risk, but not to zero.

When is an HSV infection an emergency?

Newborn symptoms, eye involvement, altered mental status, severe neurological symptoms and disseminated disease require urgent medical care.

Key takeaways

Test active lesions with type-specific NAAT when available; treat every first genital episode; distinguish episodic from daily suppressive regimens; and counsel about asymptomatic transmission. Pregnancy, eye disease, severe illness and suspected resistance demand specialized assessment.

References

  1. Centers for Disease Control and Prevention. Genital herpes: STI treatment guidelines. Atlanta: CDC; accessed 8 Nov 2026.
  2. Centers for Disease Control and Prevention. About genital herpes. Atlanta: CDC; accessed 8 Nov 2026.

Medical disclaimer: This article is for education and does not replace clinical diagnosis or a prescription. Antiviral doses require individual adjustment, especially during pregnancy, renal impairment or immunosuppression. Seek urgent care for severe or neurological symptoms or eye involvement.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *